RXRX (Recursion Pharmaceuticals) Beta: 3.2674 (As of Jul. 04, 2026)


RXRX Recursion Pharmaceuticals Inc RXRX
77 GF Score
Price $3.82
GF Value $4.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Beta?

Recursion Pharmaceuticals RXRX +3.54% 77 Beta is 3.2674 as of Jul. 04, 2026. GuruFocus rates RXRX with a GF Score™ of 77/100 and a GF Value™ of $4.14 (Fairly Valued). The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-04), Recursion Pharmaceuticals's Beta is 3.2674.


Recursion Pharmaceuticals  (NAS:RXRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Recursion Pharmaceuticals Beta Related Terms


Recursion Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Beta Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 1.04 2.76

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 1.45 2.28 2.76 2.90

RXRX vs ABSI, GLUE, ANAB: Beta Comparison

For the Biotechnology subindustry, Recursion Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recursion Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's Beta falls into.


RXRX
77GF Score
Recursion Pharmaceuticals Inc RXRX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.2674 mean?
Recursion Pharmaceuticals (RXRX) has a Beta of 3.2674 as of Jul. 04, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Recursion Pharmaceuticals and its competitors.
Is Recursion Pharmaceuticals' Beta too high?
Recursion Pharmaceuticals' current Beta is 3.2674. Overall, Recursion Pharmaceuticals has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Beta compare to ABSI and GLUE?
Recursion Pharmaceuticals' Beta of 3.2674 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Beta is 3.2674. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (RXRX) is currently considered Fairly Valued. The stock's GF Value™ is $4.14, compared to a current price of $3.82 — trading 7.9% below its estimated fair value. The current Beta is 3.2674. Recursion Pharmaceuticals' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Recursion Pharmaceuticals (RXRX), the current Beta is 3.2674 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of $3.82 is trading 7.9% below its estimated GF Value™ of $4.14. GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.

Key valuation signals for RXRX:

  • Beta: 3.2674
  • GF Value™: $4.14 vs. price of $3.82 (7.9% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
77GF Score

Get the complete analysis for RXRX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.82
Price
$4.14
GF Value